+

WO2018104772A1 - Préparation de type à absorption percutanée - Google Patents

Préparation de type à absorption percutanée Download PDF

Info

Publication number
WO2018104772A1
WO2018104772A1 PCT/IB2017/001501 IB2017001501W WO2018104772A1 WO 2018104772 A1 WO2018104772 A1 WO 2018104772A1 IB 2017001501 W IB2017001501 W IB 2017001501W WO 2018104772 A1 WO2018104772 A1 WO 2018104772A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
drug
containing layer
tramadol
transdermal
Prior art date
Application number
PCT/IB2017/001501
Other languages
English (en)
Japanese (ja)
Inventor
傑 石川
貴史 才
Original Assignee
王子ホールディングス株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 王子ホールディングス株式会社 filed Critical 王子ホールディングス株式会社
Publication of WO2018104772A1 publication Critical patent/WO2018104772A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Definitions

  • the present invention relates to a transdermal preparation containing tramadol or a pharmaceutically acceptable salt thereof as an active ingredient.
  • Tramadol ((1RS, 2RS) -2-[(dimethylamino) methyl] -1- (3-methoxyphenyl) cyclohexanol) is one of opioid analgesics and is mild in WHO cancer pain therapy. It is classified as a weak opioid used for moderate to moderate pain. The analgesic action of tramadol is thought to result from the suppression of nociceptive transmission by binding to the ⁇ opioid receptor and the activation of the descending pain suppression system by inhibiting serotonin and noradrenaline reuptake.
  • Tramadol is effective in alleviating pain and chronic pain in various cancers, and is currently used as tramadol hydrochloride in dosage forms such as injections, oral preparations, and suppositories.
  • Tramadol hydrochloride has a chemical structure of the following formula (I):
  • Patent Document 1 shows that when menthol, O-ethylmenthol, or limonene was added as an absorption enhancer to tramadol-containing hydrogel, the transdermal absorbability of tramadol was enhanced more than when cholic acid was added as an absorption enhancer.
  • Patent Document 2 discloses that as an absorption promoter, pentazocine which is an opioid receptor antagonist is obtained by using a compound selected from the group consisting of isopropyl myristate and glyceryl monocaprylate, glyceryl monocaprate and glyceryl monolaurate. It is disclosed that percutaneous absorption is improved.
  • Patent Document 2 also mentions tramadol hydrochloride as an opioid receptor antagonist, but does not disclose an example showing that the percutaneous absorption of tramadol is improved by the above-mentioned absorption enhancer.
  • Patent Document 3 discloses that high skin permeability of tramadol was obtained by formulating free tramadol as an organogel containing a fatty acid ester and a glycerin fatty acid ester. On the other hand, Patent Document 3 also discloses that tramadol hydrochloride-containing organogel had extremely low skin permeability for tramadol.
  • the present invention provides a transdermally absorbable preparation containing tramadol or a pharmaceutically acceptable salt thereof, in which bleeding is not caused and coagulation property is maintained while maintaining the skin permeability of tramadol, and It aims at providing the manufacturing method made from a transdermal absorption type.
  • the present inventors have found that high skin permeability of tramadol can be obtained by using a fatty acid alkanolamide as an absorption accelerator. Further, the present inventors have found that bleeding is increased when the content of fatty acid alkanolamide is increased to a certain value or more in order to further improve skin permeability, or when an absorption accelerator other than fatty acid alkanolamide is further added. It has been found that there is a new problem that occurs and the cohesiveness may decrease. As a result of further studies, it was found that even in such a case, blending silicic acid in the drug-containing layer can prevent bleeding and maintain good cohesiveness. Furthermore, it was unexpectedly found that tramadol exhibits high storage stability in the drug-containing layer thus obtained. The present inventors have further studied based on these findings and have completed the present invention. That is, the present invention is as follows.
  • a transdermal preparation having a support and a drug-containing layer, wherein the drug-containing layer contains tramadol or a pharmaceutically acceptable salt thereof, a fatty acid alkanolamide, silicic acid, and an adhesive A transdermal absorption preparation.
  • the pressure-sensitive adhesive contains a rubber-based resin as a main component.
  • the rubber-based resin contains a styrene-isoprene-styrene block copolymer and a tackifier.
  • the fatty acid alkanolamide is at least one selected from lauric acid diethanolamide, oleic acid diethanolamide, and lauric acid monoisopropanolamide. Mold formulation.
  • transdermal absorption preparation according to [7], wherein the fatty acid ester is at least one selected from isopropyl myristate, isopropyl palmitate, and hexyl laurate.
  • the organic acid is at least one selected from acetic acid, caprylic acid, oleic acid, and isostearic acid.
  • the skin permeability of tramadol can be improved while maintaining good aggregation.
  • the storage stability of tramadol in the drug-containing layer can be enhanced. Therefore, the present invention can provide a means for administering tramadol with improved convenience.
  • the “percutaneous absorption preparation” refers to a parenteral preparation in which an active ingredient is absorbed through the skin and delivered to the bloodstream.
  • the transdermally absorbable preparation of the present invention is a patch having a support and a drug-containing layer, and examples thereof include a tape, a poultice, and a plaster.
  • the transdermally absorbable preparation of the present invention may be a matrix-type patch preparation containing an adhesive in the drug-containing layer, and a controlled-release membrane and skin for adjusting the transdermal absorption of the drug on the skin-applied side of the drug-containing layer It may be a reservoir-type patch preparation that further has an adhesive layer for sticking to the skin. With such a structure, tramadol can be efficiently transdermally absorbed.
  • a matrix-type patch preparation is preferable.
  • the matrix-type patch preparation will be described as an example, but the present invention is not limited thereto.
  • the drug-containing layer contains tramadol or a pharmaceutically acceptable salt thereof.
  • Tramadol has analgesic action and is used to treat pain.
  • the pain is not particularly limited as long as it can be alleviated by tramadol.
  • pain in various cancers chronic pain (eg, nociceptive pain (eg, low back pain, osteoarthritis, etc.), Neuropathic pain (eg, postherpetic neuralgia, diabetic neuropathic pain, and psychogenic pain).
  • compositions of tramadol include acid addition salts such as inorganic acid salts such as hydrochloride, hydrobromide, nitrate, sulfate, phosphate and the like; and organic acid salts such as, for example, Formate, acetate, trifluoroacetate, ascorbate, benzoate, cinnamate, citrate, fumarate, glutamate, tartrate, oxalate, glutarate, camphorate, adipine Acid salt, sorbate, lactate, maleate, linoleate, linolenate, malate, malonate, mandelate, methanesulfonate (mesylate), phthalate, salicylate, stearin Acid salt, isostearate, succinate, propionate, butyrate, pamoate, p-toluenesulfonate (tosylate), benzenesulfonate (besylate), etc. It is, but is, but
  • Tramadol or a pharmaceutically acceptable salt thereof may be used in crystalline form.
  • the crystal may be formed only from tramadol or a pharmaceutically acceptable salt thereof, or may form a co-crystal or a solvate (for example, a hydrate, preferably a monohydrate). Good. Any of tramadol or a pharmaceutically acceptable salt thereof may be used alone or in combination of two or more. In the present invention, it is preferable to use tramadol hydrochloride, which has already been established to be useful for intramuscular administration and oral administration, as a pain therapeutic agent.
  • the content of tramadol or a pharmaceutically acceptable salt thereof in the transdermal preparation of the present invention is an effective amount for the treatment of pain.
  • the “effective amount” is an amount capable of achieving a blood concentration of tramadol effective for treating pain when the transdermally absorbable preparation of the present invention is applied to the skin of a living body.
  • Such content can be adjusted as appropriate based on information on the pharmacokinetics of oral administration, and may vary depending on the administration subject, disease, symptoms, and the like.
  • the amount is preferably 1 to 40% by mass, more preferably 5 to 35% by mass, and still more preferably 10 to 30% by mass with respect to the drug-containing layer (that is, based on the total mass of the drug-containing layer; the same shall apply hereinafter).
  • the blood concentration of tramadol effective for the treatment of pain can be similar to that of intramuscular or oral administration of tramadol.
  • a blood concentration effective for treating pain can be achieved by adjusting the skin permeation rate of tramadol.
  • the skin permeation rate can be adjusted by any means such as adjusting the content of tramadol or a pharmaceutically acceptable salt thereof in the drug-containing layer, or adding an absorption enhancer described later to the drug-containing layer. It can be carried out.
  • the skin permeation rate of tramadol means a value measured by an in vitro skin permeability test described in Examples described later.
  • the skin permeation rate of tramadol is usually 40 ⁇ g / cm 2 / hour or more, preferably 50 ⁇ g / cm 2 / hour or more, more preferably 60 ⁇ g / cm 2 / hour or more. If the skin permeation rate is 40 ⁇ g / cm 2 / hour or more, a sufficient blood concentration can be obtained.
  • the skin permeation rate of tramadol is usually less than 100 [mu] g / cm 2 / time, preferably less than 90 [mu] g / cm 2 / hour, more preferably less than 80 [mu] g / cm 2 / hour. If the skin permeation rate is less than 100 ⁇ g / cm 2 / hour, the blood concentration does not become too high, which is preferable from the viewpoint of safety.
  • Basic Compound When an acid addition salt is used as a pharmaceutically acceptable salt of tramadol, it is preferable to contain a basic compound in the drug-containing layer.
  • basic compounds include inorganic bases and organic bases, such as low molecular weight compounds containing basic nitrogen (for example, ethanolamine, isopropanolamine, diethanolamine, diisopropanolamine, triethanolamine, triisopropanolamine, etc.
  • Aliphatic alkanolamine polymer compound containing basic nitrogen (for example, aminoalkyl methacrylate copolymer E, polyvinyl acetal diethylaminoacetate, polyvinylpyridine, etc.); basic alkali metal salt (for example, sodium acetate, potassium acetate, boric acid) Sodium, sodium carbonate, sodium hydrogen carbonate, trisodium citrate, sodium silicate); alkali metal hydroxides (for example, sodium hydroxide, potassium hydroxide, etc.).
  • basic acrylic resins such as Eudragit series (Eudragit E100, Eudragit EPO: Evonik Industries company make). Of these, inorganic bases and aliphatic alkanolamines are preferable, and sodium hydroxide, potassium hydroxide, and diisopropanolamine are more preferable.
  • a basic compound can be used individually or in mixture of 2 or more types.
  • the content of the basic compound is preferably 0.5 to 3 equivalents, more preferably 0.7 to 2 equivalents, relative to the equivalent amount of the pharmaceutically acceptable salt of tramadol.
  • the content of the basic compound is preferably 0.1 to 35% by mass, more preferably 0.5 to 30% by mass, and more preferably 1 to 25% by mass with respect to the drug-containing layer. More preferably.
  • the basic compound acts on a pharmaceutically acceptable salt of tramadol, and the skin permeability of tramadol is improved.
  • the effect of improving the skin permeability becomes more remarkable as compared with the case where the content is outside the above range.
  • the drug-containing layer contains a fatty acid alkanolamide as an absorption accelerator.
  • Fatty acid alkanolamides for example C 12 saturated at ⁇ C 18, or one or more double bonds (preferably, 1 or two double bonds) and fatty acid moieties having, C 2 substituted with for example one or more hydroxy ⁇ C 6 alkyl (preferably, monohydroxy C 2 ⁇ C 4 alkyl) comprises a alkanolamide moiety or di alkanolamide moiety containing, for example, lauric acid diethanolamide, palmitic acid diethanolamide, stearic acid diethanolamide, Examples include oleic acid diethanolamide and lauric acid monoisopropanolamide. Of these, lauric acid diethanolamide, oleic acid diethanolamide, and lauric acid monoisopropanolamide are preferable.
  • Fatty acid alkanolamides can be used alone or in admixture of two or more.
  • the content of the fatty acid alkanolamide in the transdermal preparation of the present invention is 15% by mass or less (for example, 14% by mass or less, 13% by mass or less, 12% by mass or less) with respect to the total mass of the drug-containing layer. 11 mass% or less, 10 mass% or less, 9 mass% or less, 8 mass% or less, 7 mass% or less, 6 mass% or less, 5 mass% or less, 4 mass% or less, or 3 mass% or less)
  • the content is preferably 1 to 10% by mass, more preferably 1 to 5% by mass, and still more preferably 1 to 3% by mass. If the content of the fatty acid alkanolamide is 1% by mass or more, it is possible to give a skin permeation rate of tramadol that can achieve a blood concentration effective for the treatment of pain.
  • the drug-containing layer may further contain an absorption enhancer other than the fatty acid alkanolamide.
  • the absorption enhancer other than the fatty acid alkanolamide may be any compound that has been recognized to promote skin permeation in transdermal administration, for example, acetic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid.
  • Oxyethylene fatty acid esters aliphatic or aromatic alcohols such as decanol, lauryl alcohol, myristyl alcohol, oleyl alcohol, isostearyl alcohol, cetyl alcohol, hexyl decanol, octyldodecanol, benzyl alcohol, or ethers thereof; carbon number 3 To 8 polyhydric alcohols (eg, propylene glycol, 1,3-butanediol, , 4-butanediol, glycerin, dipropylene glycol, octanediol, etc.); phenol ethers such as polyoxyethylene nonylphenyl ether, polyoxyethylene octylphenyl ether; castor oil or hydrogenated castor oil; oleoyl sarcosine, lauryldimethylamino Ionic surfactants such as betaine acetate and sodium lauryl sulfate; polyoxyethylene alkyl ether
  • Absorption accelerators other than fatty acid alkanolamides can be used singly or in combination of two or more.
  • the absorption accelerator other than the fatty acid alkanolamide is at least one selected from organic acids and fatty acid esters.
  • the organic acid is preferably at least one selected from acetic acid, caprylic acid, oleic acid, and isostearic acid.
  • the fatty acid ester is preferably at least one selected from isopropyl myristate, isopropyl palmitate, and hexyl laurate.
  • the drug-containing layer may not contain an absorption accelerator other than the fatty acid alkanolamide, and when it is included, the content thereof is, in one aspect, 1% by mass or more (for example, 2 mass% or more, 3 mass% or more, 4 mass% or more, or 5 mass% or more), 20 mass% or less (for example, 19 mass% or less, 18 mass% or less, 17 mass% or less, 16 mass% or less, 15 Mass% or less, 14 mass% or less, 13 mass% or less, 12 mass% or less, 11 mass% or less, or 10 mass% or less).
  • an absorption accelerator other than the fatty acid alkanolamide when it is included, the content thereof is, in one aspect, 1% by mass or more (for example, 2 mass% or more, 3 mass% or more, 4 mass% or more, or 5 mass% or more), 20 mass% or less (for example, 19 mass% or less, 18 mass% or less, 17 mass% or less, 16 mass% or less, 15 Mass% or less, 14 mass% or less
  • the content of the absorption accelerator other than the fatty acid alkanolamide is, for example, preferably 0 to 20% by mass, more preferably 0 to 15% by mass, and further preferably 0 to 10% by mass. Further, the total content of fatty acid alkanolamides and absorption accelerators other than fatty acid alkanolamides in the drug-containing layer may be 1% by mass or more and 25% by mass, for example, 20% by mass, unless bleeding occurs. Less than 15% by mass and less than 10% by mass.
  • the drug-containing layer contains silicic acid.
  • silicic acid means silicon dioxide (anhydrous silicic acid) or a salt thereof.
  • silicate eg, aluminum silicate, magnesium silicate, calcium silicate, silicic acid
  • Magnesium aluminum, magnesium sodium silicate, etc. preferably silicic anhydride.
  • the content of silicic acid is preferably 0.1 to 20% by mass, more preferably 0.5 to 15% by mass, and preferably 1 to 10% by mass with respect to the total mass of the drug-containing layer. More preferably. If the silicic acid content is 0.1% by mass or more, bleeding that occurs when a fatty acid alkanolamide and other absorption promoters are blended in the drug-containing layer can be suppressed, and good cohesiveness can be maintained. . Further, it is preferable to contain silicic acid in the drug-containing layer so that the total amount of fatty acid alkanolamide and other absorption accelerators is 2 to 5 parts by mass with respect to 1 part by mass of silicic acid.
  • bleeding means a phenomenon in which a liquid component oozes out from a drug-containing layer containing an adhesive, and the presence or absence of occurrence is visually evaluated as described in Examples below. it can.
  • cohesiveness is evaluated based on the cohesive strength of the pressure-sensitive adhesive investigated by the test method described in the examples described later.
  • the drug-containing layer contains an adhesive.
  • the pressure-sensitive adhesive contained in the drug-containing layer include those containing acrylic resins, rubber resins, silicone resins, and the like.
  • the pressure-sensitive adhesive preferably contains as a main component at least one selected from the group consisting of acrylic resins, rubber resins and silicone resins, and at least selected from the group consisting of rubber resins and acrylic resins. What contains 1 type as a main component is more preferable.
  • the “main component” means usually 70% by mass or more, further 80% by mass or more, further 90% by mass or more, and particularly 100% by mass with respect to the total mass of the pressure-sensitive adhesive.
  • acrylic resin for example, (meth) acrylic acid ester represented by 2-ethylhexyl acrylate, methyl acrylate, butyl acrylate, 2-hydroxyethyl acrylate, 2-ethylhexyl methacrylate and the like is used as a monomer unit.
  • acrylic resin for example, (meth) acrylic acid ester represented by 2-ethylhexyl acrylate, methyl acrylate, butyl acrylate, 2-hydroxyethyl acrylate, 2-ethylhexyl methacrylate and the like is used as a monomer unit.
  • examples thereof include a polymer or copolymer containing at least one kind.
  • acrylic acid / octyl acrylate copolymer 2-ethylhexyl acrylate / vinylpyrrolidone copolymer solution, 2-ethylexyl acrylate / N-vinyl-2-pyrrolidone / dimethacrylic acid-1 , 6-hexane glycol copolymer, acrylic ester / vinyl acetate copolymer, 2-ethylhexyl acrylate / 2-hydroxyethyl acrylate / vinyl acetate copolymer, 2-ethylhexyl acrylate / 2-ethylhexyl methacrylate / methacrylic acid
  • examples thereof include a dodecyl copolymer solution, a methyl acrylate / 2-ethylhexyl acrylate copolymer resin emulsion, and an acrylic resin alkanolamine solution.
  • DURO-TAK acrylic adhesive series
  • DURO TAK87-900A DURO TAK 87-9301, DURO TAK 87-4098, DURO TAK 387-2510, DURO TAK 87-2510, DURO TAK 387-2287, DURO TAK 87-2287, DURO TAK 87-4287, DURO TAK 387-2516, DURO TAK 87-2516, DURO TAK 87-2074, DURO TAK 387-235A, DURO TAK 387-2353, DURO TAK 87235D -2852, DURO TAK 387-2051, DURO TAK 87-2051, DURO TAK 3 7-2052, DURO TAK 87-2052, DUROTAK 387-2054, DURO TAK 87-2054, DURO TAK 87-2194, DURO TAK 87-2196: made by Henkel Corporation, GELVA series (GELV
  • rubber resins examples include styrene-isoprene-styrene block copolymer (SIS), styrene-butadiene-styrene block copolymer (SBS), styrene-butadiene rubber (SBR), styrene isoprene rubber, and polyisobutylene (PIB). ), Polybutene, butyl rubber, natural rubber, raw rubber, gum arabic, gum arabic powder, isoprene rubber and the like, preferably styrene-isoprene-styrene block copolymer (SIS).
  • SIS styrene-isoprene-styrene block copolymer
  • SBS styrene-butadiene-styrene block copolymer
  • SBR styrene-butadiene rubber
  • PIB polyisobutylene
  • Polybutene butyl rubber, natural
  • silicone-based resin examples include polymers having an organopolysiloxane skeleton and derivatives thereof. Specific examples include dimethylpolysiloxane, polymethylvinylsiloxane, polymethylphenylsiloxane, and diphenylsiloxane. Commercially available silicone resins such as BIO-PSA series (Dow Corning) may also be used.
  • one of the acrylic resin, rubber resin, and silicone resin described above is used alone, or two or more kinds are combined. Can be used. More preferred are acrylic or rubber resins.
  • the amount of the adhesive contained in the drug-containing layer is adjusted in consideration of the formation of the drug-containing layer, sufficient skin permeability of tramadol, and the like.
  • the content of the pressure-sensitive adhesive is usually 10 to 97.8% by mass, preferably 15 to 90% by mass with respect to the drug-containing layer.
  • the adhesive is a rubber-based resin
  • the content of the adhesive is preferably 10 to 97.8% by mass, more preferably 15 to 90% by mass, and further preferably 20 to 80% by mass with respect to the drug-containing layer.
  • the adhesive is an acrylic resin
  • the content of the adhesive is preferably 10 to 97.8% by mass, more preferably 15 to 90% by mass, and further preferably 20 to 80% by mass with respect to the drug-containing layer.
  • the pressure-sensitive adhesive is a silicone resin
  • it is preferably 10 to 97.8% by mass, more preferably 15 to 90% by mass, and still more preferably 20 to 80% by mass with respect to the drug-containing layer.
  • Tackifier The drug-containing layer may further contain a tackifier for improving the adhesive strength.
  • the tackifier include rosin, rosin glycerin ester, hydrogenated rosin, rosin derivatives such as hydrogenated rosin glycerin ester, alicyclic saturated hydrocarbon resin, alicyclic hydrocarbon resin, terpene resin, aliphatic saturated Hydrocarbon resin, aliphatic hydrocarbon resin, maleic resin, carnauba wax, carmellose sodium, xanthan gum, chitosan, glycerin, magnesium aluminum silicate, light anhydrous silicic acid, benzyl acetate, talc, hydroxyethyl cellulose, hydroxypropyl cellulose, hypromellose, Examples include polyacrylic acid, sodium polyacrylate, partially neutralized polyacrylic acid, and polyvinyl alcohol.
  • tackifier commercially available products such as Alcon series (Arakawa Chemical Co., Ltd.), Pine Crystal series (Arakawa Chemical Co., Ltd.), Clearon series (Yasuhara Chemical Co., Ltd.), YS Resin Series (Yasuhara Chemical Co., Ltd.), etc. You may use suitably.
  • the rubber-based resin when used as an adhesive, it is preferable to use a hydrogenated rosin glycerin ester, an alicyclic saturated hydrocarbon resin, a terpene resin, or an aliphatic saturated hydrocarbon resin as a tackifier. Rosin glycerin ester is more preferred.
  • a tackifier can be used individually by 1 type or in combination of 2 or more types.
  • the content of the tackifier is preferably 5 to 70% by mass, preferably 10 to 60% by mass with respect to the drug-containing layer when a rubber-based resin is used as the adhesive in consideration of sufficient adhesive strength as a patch. % Is more preferable, and 15 to 50% by mass is more preferable.
  • an acrylic resin is used as the pressure-sensitive adhesive
  • the content is preferably 0 to 40% by mass, more preferably 0 to 30% by mass, and still more preferably 0 to 20% by mass with respect to the drug-containing layer.
  • a silicone resin is used as the pressure-sensitive adhesive, the content is preferably 0 to 30% by mass, more preferably 0 to 20% by mass, and still more preferably 0 to 10% by mass with respect to the drug-containing layer.
  • Plasticizer The drug-containing layer may further contain a plasticizer.
  • Plasticizers include petroleum oils (eg, paraffinic process oil, naphthenic process oil, aromatic process oil, liquid paraffin, etc.), squalane, squalene, vegetable oils (eg, olive oil, camellia oil, castor oil, tall Oil, peanut oil, etc.), silicone oil, dibasic acid ester (eg, dibutyl phthalate, dioctyl phthalate, etc.), liquid rubber (eg, polybutene, liquid isoprene rubber, etc.), diethylene glycol, polyethylene glycol, salicylic acid glycol, crotamiton, etc. It is done.
  • plasticizer you may use suitably what is marketed, such as the Moresco white series (made by Moresco), the high call series (made by Kaneda).
  • the rubber-based resin is used as an adhesive
  • liquid paraffin is preferably used as a plasticizer.
  • a plasticizer can be used individually by 1 type or in combination of 2 or more types.
  • the content of the plasticizer is adjusted in consideration of sufficient permeability of tramadol and maintenance of sufficient cohesion as a transdermal preparation.
  • a rubber-based resin is used as the adhesive, it is preferably 0 to 70% by mass, more preferably 0 to 60% by mass, and still more preferably 0 to 40% by mass with respect to the drug-containing layer.
  • an acrylic resin is used as the pressure-sensitive adhesive, the content is preferably 0 to 50% by mass, more preferably 0 to 40% by mass, and still more preferably 0 to 30% by mass with respect to the drug-containing layer.
  • a silicone resin is used as the pressure-sensitive adhesive, the total amount is preferably 0 to 40% by mass, more preferably 0 to 30% by mass, and further preferably 0 to 20% by mass with respect to the drug-containing layer.
  • the drug-containing layer further contains a known additive such as a pH adjuster, a crosslinking agent, an antioxidant, a colorant, an ultraviolet absorber, a filler, or an antiseptic, as necessary. Also good.
  • a known additive such as a pH adjuster, a crosslinking agent, an antioxidant, a colorant, an ultraviolet absorber, a filler, or an antiseptic, as necessary. Also good.
  • the pH adjusting agent can be used to adjust the pH of the drug-containing layer for the purpose of improving the solubility, stability, and skin permeability of tramadol and improving the safety to the skin.
  • the pH adjusting agent may be any compound as long as it is an acid or base or a salt thereof that is usually used for pH adjustment in the pharmaceutical field.
  • crosslinking agents include thermosetting resins such as amino resins, phenol resins, epoxy resins, alkyd resins, and unsaturated polyesters, isocyanate compounds, blocked isocyanate compounds, organic crosslinking agents, and inorganic crosslinking agents such as metals or metal compounds. Is mentioned. Among these, an isocyanate compound or a blocked isocyanate compound is preferable.
  • antioxidants examples include tocopherol and ester derivatives thereof, ascorbic acid, ascorbic acid stearate, nordihydroguaiaretic acid, dibutylhydroxytoluene (BHT), butylhydroxyanisole and the like.
  • colorant examples include indigo carmine, yellow iron oxide, yellow iron sesquioxide, carbon black, caramel, photosensitive element 201, Kumazasa extract, black iron oxide, ketket, zinc oxide, titanium oxide, iron sesquioxide, amaranth, water
  • examples include sodium oxide, talc, copper chlorophyllin sodium, green leaf extract powder, d-borneol, octyldodecyl myristate, methylene blue, ammonium manganese phosphate, and rose oil.
  • Examples of the ultraviolet absorber include amino acid compounds, benzophenone compounds, cinnamic acid derivatives, cyanoacrylate derivatives, p-aminobenzoic acid derivatives, anthranilic acid derivatives, salicylic acid derivatives, coumarin derivatives, imidazoline derivatives, pyrimidine derivatives, dioxane derivatives, and the like. Can be mentioned.
  • Fillers include calcium carbonate, magnesium carbonate, sodium carbonate, ammonium carbonate, potassium carbonate, potassium bicarbonate, silicate (eg, aluminum silicate, magnesium silicate, calcium silicate, magnesium aluminum silicate, magnesium silicate Sodium), magnesium hydroxide, barium sulfate, calcium sulfate, calcium zincate, zinc oxide, titanium oxide and the like.
  • silicate eg, aluminum silicate, magnesium silicate, calcium silicate, magnesium aluminum silicate, magnesium silicate Sodium
  • magnesium hydroxide eg, barium sulfate, calcium sulfate, calcium zincate, zinc oxide, titanium oxide and the like.
  • preservative examples include ethyl paraoxybenzoate, propyl paraoxybenzoate, and butyl paraoxybenzoate.
  • the total content of other optional components is preferably 0 to 10% by mass, more preferably 0 to 5% by mass with respect to the drug-containing layer.
  • the area of the drug-containing layer in the transdermally absorbable preparation of the present invention can be appropriately adjusted according to the content of tramadol or a pharmaceutically acceptable salt thereof, the skin permeation rate of tramadol, and the like.
  • the area of the drug-containing layer is in the range of 2 to 140 cm 2 , preferably 10 to 100 cm 2 , more preferably 20 to 70 cm 2 .
  • the shape of the drug-containing layer is not particularly limited, and may be a square, a rectangle, a circle, an ellipse, or the like.
  • the thickness of the drug-containing layer in the transdermal preparation of the present invention can be appropriately adjusted according to the type of pressure-sensitive adhesive, the content of tramadol or a pharmaceutically acceptable salt thereof, the skin permeation rate of tramadol, and the like. Yes, it is not particularly limited.
  • the thickness of the drug-containing layer is in the range of 20 to 300 ⁇ m, preferably 25 to 200 ⁇ m, more preferably 30 ⁇ m to 150 ⁇ m.
  • tramadol shows a high storage stability compared to the percutaneous absorption preparation containing no fatty acid alkanolamide.
  • “storage stability” refers to the ratio of tramadol remaining in the drug-containing layer (% to the starting content (%) after the transdermal preparation is hermetically packaged in an aluminum bag and stored at 60 ° C. for 4 weeks. )), which is examined by the test method described in the examples below. When the content (%) at the start is 98% or more, it is evaluated that the storage stability is high.
  • a transdermal preparation containing no fatty acid alkanolamide in the drug-containing layer may have relatively high skin irritation, but the transdermal preparation of the present invention containing the fatty acid alkanolamide in the drug-containing layer is the same. Although it exhibits a degree of tramadol skin permeability, it exhibits low skin irritation compared to a transdermal patch with no fatty acid alkanolamide in the drug-containing layer.
  • the transdermal preparation is applied to the left and right torso parts of guinea pigs that have been shaved and shaved, and the transdermal preparation is removed after 24 hours, and 24, 48, and 72 are removed from the application.
  • PI skin irritation index
  • One embodiment of the drug-containing layer in the transdermally absorbable preparation of the present invention includes those containing tramadol or a pharmaceutically acceptable salt thereof, a fatty acid alkanolamide, silicic acid, and an adhesive.
  • tramadol or a pharmaceutically acceptable salt thereof tramadol acid addition salt (particularly hydrochloride) is preferable.
  • the drug-containing layer preferably contains a basic compound.
  • the fatty acid alkanolamide lauric acid diethanolamide, oleic acid diethanolamide, and lauric acid monoisopropanolamide are preferable.
  • As the silicic acid anhydrous silicic acid is preferable.
  • an adhesive what contains at least 1 sort (s) chosen from the group which consists of rubber-type resin and acrylic resin as a main component is preferable.
  • the content of tramadol or a pharmaceutically acceptable salt thereof is 1 to 40% by mass
  • the content of basic compound is 0.1 to 35% by mass
  • the content of fatty acid alkanolamide is 1 to It is preferable that the content is 9% by mass
  • the content of silicic acid is 0.1 to 20% by mass
  • the content of the adhesive is 10 to 97.8% by mass.
  • the drug-containing layer in the transdermally absorbable preparation of the present invention contains tramadol or a pharmaceutically acceptable salt thereof, a fatty acid alkanolamide, an absorption accelerator other than the fatty acid alkanolamide, silicic acid, and an adhesive.
  • tramadol or a pharmaceutically acceptable salt thereof tramadol acid addition salt (particularly hydrochloride) is preferable.
  • the drug-containing layer preferably contains a basic compound.
  • the fatty acid alkanolamide lauric acid diethanolamide, oleic acid diethanolamide, and lauric acid monoisopropanolamide are preferable.
  • the absorption accelerator other than the fatty acid alkanolamide is preferably at least one selected from fatty acid esters and organic acids.
  • the fatty acid ester is preferably isopropyl myristate, isopropyl palmitate, or hexyl laurate.
  • the organic acid is preferably acetic acid, caprylic acid, oleic acid, and isostearic acid.
  • As the silicic acid anhydrous silicic acid is preferable.
  • As an adhesive what contains at least 1 sort (s) chosen from the group which consists of rubber-type resin and acrylic resin as a main component is preferable.
  • the content of tramadol or a pharmaceutically acceptable salt thereof is 1 to 40% by mass, the content of basic compound is 0.1 to 35% by mass, and the content of fatty acid alkanolamide is 1 to 15 mass%, content of absorption accelerator other than fatty acid alkanolamide is 1 to 20 mass%, content of silicic acid is 0.1 to 20 mass%, and content of adhesive is 10 to 96.8 mass% Preferably there is.
  • a drug-impermeable, stretchable or non-stretchable support can be used.
  • a support is not particularly limited as long as it is usually used in the field of pharmaceuticals.
  • polyethylene, polypropylene, polybutadiene, ethylene vinyl acetate copolymer, polyvinyl chloride, polyester (polyethylene terephthalate, etc.) examples thereof include synthetic resin films or sheets such as nylon and polyurethane, or laminates, porous bodies, foams, and films in which aluminum is vapor-deposited.
  • paper, woven fabric, nonwoven fabric, or a laminate of these and a film can also be used as the support.
  • the transdermally absorbable preparation of the present invention may further have a release liner.
  • the release liner is laminated on the surface of the drug-containing layer laminated on the support opposite to the surface in contact with the support, and protects the drug-containing layer until the transdermal preparation is applied to the skin. can do.
  • the release liner is not particularly limited as long as it is impermeable to at least tramadol or a pharmaceutically acceptable salt thereof in the drug-containing layer.
  • the release liner is made of a polymer material such as polyethylene, polypropylene, polyester, polyethylene terephthalate. Film, a film in which aluminum is vapor-deposited, and a film in which silicone oil or the like is coated on paper.
  • the transdermally absorbable preparation of the present invention can be produced according to a known method. Prepare a mixture containing tramadol or a pharmaceutically acceptable salt thereof, fatty acid alkanolamide, silicic acid, and adhesive, and other ingredients as required, and apply or spread this mixture on a release liner to create a drug It can manufacture by forming a content layer and bonding a support body to this drug content layer.
  • the components in the drug-containing layer are added to an organic solvent so as to have the content, and mixed and stirred to prepare a coating solution.
  • organic solvent ethyl acetate, hexane, pentane, heptane, toluene, cyclohexane, chloroform, methylene chloride, methanol, ethanol, isopropyl alcohol, methyl ethyl ketone, cyclohexanone, acetone, a mixed solvent thereof or the like
  • the content of the organic solvent in the coating solution is not particularly limited, and is, for example, 30 to 90% by mass, preferably 40 to 80% by mass with respect to the entire coating solution.
  • this coating solution is applied or spread on a release liner, the solvent in the coating solution is evaporated to form a drug-containing layer, and then a support is attached to obtain a transdermal absorption preparation.
  • a transdermal preparation can be obtained by applying or spreading a coating liquid on a support, evaporating the solvent in the coating liquid to form a drug-containing layer, and then attaching a release liner.
  • a method in which a coating solution is applied or spread on a release liner, a solvent in the coating solution is evaporated to form a drug-containing layer, and then a support is bonded together is preferable.
  • Coating or spreading of the coating solution can be performed using a knife coater, comma coater, reverse coater, or die coater. Although an example of a manufacturing flow is shown in FIG. 1, it is not limited to this.
  • the components in the drug-containing layer are heated and melted, and the melt is applied or spread on a release liner to form a drug-containing layer, and then the support is formed.
  • a percutaneous absorption type preparation can also be produced by bonding.
  • a transdermal preparation may be produced by laminating a release liner.
  • the treatment of pain by the transdermal preparation of the present invention can be performed by directly applying the transdermal preparation of the present invention to the skin of the subject and transdermally administering tramadol.
  • the subject in the present invention is a mammal such as a human, preferably a human.
  • tramadol When tramadol is transdermally administered by the transdermally absorbable preparation of the present invention, the content of tramadol or a pharmaceutically acceptable salt thereof in the drug-containing layer so as to achieve a blood concentration effective for the treatment of pain
  • the percutaneously absorbable preparation of the present invention is applied to the skin after appropriately adjusting the skin permeation rate of tramadol, the area of the drug-containing layer, the thickness of the drug-containing layer and the like.
  • the percutaneous absorption type preparation of the present invention may be applied to the skin of any part of the body as long as it can be applied.
  • it can be applied to the upper arm, abdomen, chest, neck, waist back, buttocks or legs. Can be pasted.
  • Transdermal administration of the transdermal preparation of the present invention to a subject may be combined with administration of a pharmaceutical composition containing a pharmaceutical ingredient other than tramadol, if necessary.
  • the administration form may be simultaneous administration or administration with a time difference
  • the pharmaceutical composition may be intravenous, intraperitoneal, subcutaneous and intramuscular, oral, topical or transmucosal. It can be administered by various routes including:
  • a pharmaceutical composition containing a pharmaceutical ingredient other than tramadol is administered to a subject by an administration route usually used for the pharmaceutical ingredient.
  • tramadol Pharmaceutical components other than tramadol include, but are not limited to, analgesics such as acetaminophen, nonsteroidal anti-inflammatory analgesics such as diclofenac sodium and loxoprofen sodium, and local anesthetics such as lidocaine.
  • analgesics such as acetaminophen
  • nonsteroidal anti-inflammatory analgesics such as diclofenac sodium and loxoprofen sodium
  • local anesthetics such as lidocaine.
  • Example 1 Preparation of rubber-based resin composition Styrene-isoprene-styrene block copolymer (Quintac 3570C, manufactured by Nippon Zeon Co., Ltd.), hydrogenated rosin glycerin ester (Pine Crystal KE-311, manufactured by Arakawa Chemical Industries, Ltd.), polyisobutylene (Oppanol B12SFN) (Manufactured by BASF) was dissolved in a mixed solution of toluene and hexane so as to have a solid concentration of 30% to obtain a rubber-based resin composition.
  • Ingredient name Mixing ratio Quintac 3570C (made by Nippon Zeon) 45% Pine Crystal KE-311 (Arakawa Chemical Industries) 45% Opanol B12SFN (BASF) 10%
  • the coating solution was applied on a release film (film binder 75E-0010 BD: manufactured by Fujimori Kogyo Co., Ltd.) so that the thickness after evaporation of the solvent was about 75 ⁇ m and dried, and then the support (EH-1212: Nippon Viylene Co., Ltd.) was bonded to produce a transdermal absorption preparation.
  • a release film film binder 75E-0010 BD: manufactured by Fujimori Kogyo Co., Ltd.
  • the support EH-1212: Nippon Viylene Co., Ltd.
  • Examples 2-7 As shown in Table 1, the same procedure as in Example 1 was performed except that the absorption accelerator other than the fatty acid alkanolamide was changed to isopropyl palmitate, hexyl laurate, acetic acid, caprylic acid, oleic acid, and isostearic acid, respectively.
  • the transdermal patches of Examples 2 to 7 were produced.
  • Examples 8 and 9 As shown in Table 1, transdermal patches of Examples 8 and 9 were produced in the same manner as in Example 1 except that the fatty acid alkanolamide was changed to oleic acid diethanolamide and lauric acid monoisopropanolamide, respectively. .
  • Comparative Example 1 As shown in Table 2, a transdermal patch of Comparative Example 1 was produced in the same manner as in Example 1 except that no silicic acid was blended and the blending ratio of the rubber-based resin composition was increased accordingly. .
  • Comparative Examples 2-10 As shown in Table 2, absorption accelerators other than fatty acid alkanolamides are hexyl laurate, oleic acid, isostearic acid, propylene glycol monocaprylate, isostearyl alcohol, propylene glycol, 1,3-butylene glycol, triacetin, and Comparative percutaneously absorbable patches of Comparative Examples 2 to 10 were produced in the same manner as in Comparative Example 1 except that propylene carbonate was used.
  • Comparative Example 11 As shown in Table 2, the transdermal patch of Comparative Example 11 was produced in the same manner as in Example 8 except that no silicic acid was blended and the blending ratio of the rubber-based resin composition was increased accordingly. .
  • Comparative Example 12 As shown in Table 2, the transdermal patch of Comparative Example 12 was produced in the same manner as in Example 9 except that the silicic acid was not blended and the blending ratio of the rubber-based resin composition was increased accordingly. .
  • Comparative Examples 13-15 As shown in Table 3, lauric acid diethanolamides were respectively converted into POE (4.2) lauryl ether (BL-4.2: manufactured by Nikko Chemicals), sorbitan monolaurate (SPAN20: manufactured by Croda Japan), and glyceryl monocaprylate. Transdermal absorption patches of Comparative Examples 13 to 15 were produced in the same manner as in Example 1 except that (Capmul 708G: manufactured by ABITEC Corporation) was used.
  • Test Example 1 In vitro skin permeability test
  • an in vitro skin permeability test was performed according to the following procedure. After affixing the transdermal patches of each Example and Comparative Example to the horny layer side of 7-week-old male hairless mouse isolated skin (Hos: HR-1 system, manufactured by Hoshino Laboratory Animal Breeding Co., Ltd.), 32 It was attached to a vertical diffusion cell (trade name: Palm Cell Vertical TP-6: manufactured by Beadrex Co., Ltd.) in which warm water of 5 ° C. was circulated around the outer periphery so that the skin basement membrane was on the receiver side.
  • a vertical diffusion cell trade name: Palm Cell Vertical TP-6: manufactured by Beadrex Co., Ltd.
  • PBS phosphate buffered saline
  • Test example 2 The cohesiveness of the transdermal patches of each Example and Comparative Example was evaluated by the following procedure. The release liner was removed from the transdermal absorption patch, the surface of the drug-containing layer was strongly suppressed with a finger, the amount of adhesive remaining on the finger when peeled off was visually observed, and evaluated according to the following criteria. A: It has a good cohesive strength without leaving an adhesive. B: Adhesive is only slightly left and has cohesive strength. C: A large amount of adhesive remains and the cohesive force is weak.
  • the obtained results are shown in Tables 1 to 3.
  • the evaluations of the transdermal patches of Examples 1 to 9 and Comparative Examples 1 to 15 were all A or B and had sufficient cohesiveness as the transdermal patches.
  • the evaluation of the transdermal patches of Examples 1, 3, 8, and 9 was A, whereas Comparative Examples 1, 2, 11, and 12 in which no silicic acid anhydride was blended.
  • the evaluation of the transdermal patch is B, suggesting that higher cohesiveness can be obtained when silicic anhydride is added to the drug-containing layer.
  • Test Example 3 (Bleeding evaluation) About the transdermal absorption type patch of each Example and the comparative example, the surface of the removed release liner was observed visually and bleeding was evaluated. ⁇ : No bleeding ⁇ : With bleeding
  • Test Example 4 Stability test The transdermal patches of Examples and Comparative Examples were hermetically packaged in aluminum bags and stored at 60 ° C. for 4 weeks, and then the tramadol content in the drug-containing layer of each patch was measured by the HPLC method. A sample preparation method and HPLC measurement conditions are shown below.
  • Content at start (%) tramadol content in the stored sample / tramadol content in the initial sample ⁇ 100
  • Test Example 5 (guinea pig skin primary irritation test) Six week old Hartley male guinea pigs were used. On the day before administration, the left and right torso parts of the guinea pig were shaved and shaved to a size of about 4 ⁇ 8 cm. On the next day of cutting, the patches (diameter 15 mm) of Examples 1, 2, 6 and Comparative Examples 13 to 15 were affixed to the left and right torso parts and fixed with an adhesive foam pad M (manufactured by 3M Healthcare). A polyethylene film tape (Keeppore A, manufactured by Nichiban Co., Ltd.) was wound around the body and fixed with Silky Tech (ALCARE No. 5).
  • a polyethylene film tape (Keeppore A, manufactured by Nichiban Co., Ltd.) was wound around the body and fixed with Silky Tech (ALCARE No. 5).
  • irritation is based on P.I. I. When I was 0, it was designated as “non-irritant”, when it was greater than 0 and less than 2, “mildly irritating”, when 2 or more and less than 5, “moderately irritating”, and when 5 or more, “strongly irritating” Statistical processing was not performed during the evaluation.
  • the results are shown in Table 5. Although the skin irritation of any of the transdermal patches was mild, the transdermal patches of Examples 1, 2 and 6 had a lower P.P. than the transdermal patches of Comparative Examples 13-15. I. I was shown. Therefore, the transdermal absorption patch of the present invention exhibits substantially the same skin irritation compared to the transdermal absorption patch that shows the same level of tramadol skin permeability but does not contain a fatty acid alkanolamide in the drug-containing layer. Was shown to be reduced.
  • a transdermal absorption preparation containing tramadol or a pharmaceutically acceptable salt thereof which has high storage stability and improved the skin permeability of tramadol while maintaining good aggregation properties. Is done. Therefore, the present invention can provide a means for administering tramadol with improved convenience.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une préparation de type à absorption percutanée comportant du tramadol ou un sel pharmaceutiquement acceptable de ce dernier, ladite préparation de type à absorption percutanée maintenant la perméabilité cutanée du tramadol sans provoquer de saignement et maintenant également l'agrégabilité. Plus précisément, la présente invention porte sur une préparation de type à absorption percutanée comprenant un support et une couche comportant un médicament, la couche comportant un médicament comportant du tramadol ou un sel pharmaceutiquement acceptable de ce dernier, un alcanolamide d'acide gras, de l'acide silicique et un adhésif.
PCT/IB2017/001501 2016-12-05 2017-12-04 Préparation de type à absorption percutanée WO2018104772A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016235652A JP6695571B2 (ja) 2016-12-05 2016-12-05 経皮吸収型製剤
JP2016-235652 2016-12-05

Publications (1)

Publication Number Publication Date
WO2018104772A1 true WO2018104772A1 (fr) 2018-06-14

Family

ID=62491661

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/001501 WO2018104772A1 (fr) 2016-12-05 2017-12-04 Préparation de type à absorption percutanée

Country Status (2)

Country Link
JP (1) JP6695571B2 (fr)
WO (1) WO2018104772A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114269330A (zh) * 2019-06-28 2022-04-01 帕斯帕特技术有限公司 透皮药物递送贴片、药物递送系统和药物递送方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7639357B2 (ja) 2020-01-31 2025-03-05 大正製薬株式会社 外用医薬組成物

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07304672A (ja) * 1994-05-06 1995-11-21 Nitto Denko Corp 経皮吸収製剤
WO2000061120A1 (fr) * 1999-04-13 2000-10-19 Hisamitsu Pharmaceutical Co., Inc. Préparations destinées à être absorbées par voie percutanée
JP2001231812A (ja) * 2000-02-25 2001-08-28 Teikoku Seiyaku Co Ltd 貼付剤用支持体およびそれを用いた外用貼付剤
WO2003013613A1 (fr) * 2001-08-10 2003-02-20 Hisamitsu Pharmaceutical Co., Inc. Preparation medicinale a absorption percutanee
JP2006169238A (ja) * 2004-11-22 2006-06-29 Hisamitsu Pharmaceut Co Inc 薬物含有貼付剤
WO2009066457A1 (fr) * 2007-11-22 2009-05-28 Medrx Co., Ltd. Composition de préparation externe comprenant du liquide ionique à base d'acides gras en tant qu'ingrédient actif
WO2010016219A1 (fr) * 2008-08-05 2010-02-11 株式会社メドレックス Préparation externe comprenant un sel d'acide gras ou un sel d'acide benzoïque d'un composant basique pharmacologiquement actif, et procédé de production de celui-ci
JP2011020997A (ja) * 2009-03-19 2011-02-03 Kyoritsu Yakuhin Kogyo Kk 外用貼付剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09143066A (ja) * 1995-11-24 1997-06-03 Sekisui Chem Co Ltd 貼付剤
JPH09208463A (ja) * 1996-02-07 1997-08-12 Tsumura & Co 経皮吸収性に優れた消炎鎮痛組成物
JP5489112B2 (ja) * 2009-09-03 2014-05-14 トーアエイヨー株式会社 貯蔵安定性を改善した貼付剤包装品

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07304672A (ja) * 1994-05-06 1995-11-21 Nitto Denko Corp 経皮吸収製剤
WO2000061120A1 (fr) * 1999-04-13 2000-10-19 Hisamitsu Pharmaceutical Co., Inc. Préparations destinées à être absorbées par voie percutanée
JP2001231812A (ja) * 2000-02-25 2001-08-28 Teikoku Seiyaku Co Ltd 貼付剤用支持体およびそれを用いた外用貼付剤
WO2003013613A1 (fr) * 2001-08-10 2003-02-20 Hisamitsu Pharmaceutical Co., Inc. Preparation medicinale a absorption percutanee
JP2006169238A (ja) * 2004-11-22 2006-06-29 Hisamitsu Pharmaceut Co Inc 薬物含有貼付剤
WO2009066457A1 (fr) * 2007-11-22 2009-05-28 Medrx Co., Ltd. Composition de préparation externe comprenant du liquide ionique à base d'acides gras en tant qu'ingrédient actif
WO2010016219A1 (fr) * 2008-08-05 2010-02-11 株式会社メドレックス Préparation externe comprenant un sel d'acide gras ou un sel d'acide benzoïque d'un composant basique pharmacologiquement actif, et procédé de production de celui-ci
JP2011020997A (ja) * 2009-03-19 2011-02-03 Kyoritsu Yakuhin Kogyo Kk 外用貼付剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114269330A (zh) * 2019-06-28 2022-04-01 帕斯帕特技术有限公司 透皮药物递送贴片、药物递送系统和药物递送方法

Also Published As

Publication number Publication date
JP2018090539A (ja) 2018-06-14
JP6695571B2 (ja) 2020-05-20

Similar Documents

Publication Publication Date Title
JP5403948B2 (ja) メマンチン含有経皮吸収製剤
US20080138388A1 (en) Transdermal Absorption Patch
JP5073124B2 (ja) ノルアドレナリン作動性・特異的セロトニン作動性抗うつ薬含有経皮吸収型貼付製剤
JP5404048B2 (ja) 貼付剤
JP4271028B2 (ja) 経皮吸収型製剤
US20080188509A1 (en) Transdermal Preparations and Method for Relieving Side Effects in Pergolide Therapy
JP6104230B2 (ja) 経皮吸収型製剤
WO2018104772A1 (fr) Préparation de type à absorption percutanée
WO2016080533A1 (fr) Agent d'absorption percutanée
JP6729584B2 (ja) 経皮吸収型貼付剤
WO2010098261A1 (fr) Préparation transdermique contenant de la rispéridone et timbre transdermique adhésif l'utilisant
JP6459148B2 (ja) 経皮吸収型製剤
JP4764337B2 (ja) 消炎鎮痛貼付剤
JP6675589B2 (ja) 経皮吸収型製剤
JP5091472B2 (ja) 粘着剤及び貼付剤
WO2016208729A1 (fr) Patch d'absorption percutanée contenant de la nalfurafine
WO2017057541A1 (fr) Préparation d'absorption transdermique
JP6512905B2 (ja) フェンタニル含有貼付剤
WO2013183407A1 (fr) Préparation adhésive cutanée absorbable par voie transdermique contenant de la mirtazapine
WO2013061588A1 (fr) Préparation absorbée par voie transdermique
JP2017007994A (ja) 経皮吸収型製剤
JP2016216384A (ja) 経皮吸収型製剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17877670

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17877670

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载